Evanston-based biopharmaceutical company Aptinyx Inc. Thursday said a drug it is studying to treat patients with painful diabetic peripheral neuropathy failed a recent clinical study.The drug, NYX-2925, did not achieve statistically significant separation from a placebo on the study’s primary endpoint, which assessed the change from baseline in average daily pain on the numeric rating scale, the company said.
Related posts
-
Illinois health department now tracking violent deaths, gun injuries
The Illinois Department of Public Health has launched a new dashboard detailing information about all violent... -
Schaumburg zoning board member nominated to succeed Dunham on village board
Schaumburg Mayor Tom Dailly nominated the village’s electrical commission chairperson and zoning board of appeals member... -
Elgin’s ‘Tent City’ residents move to hotel, cleanup begins at former homeless encampment
Forty-one residents of Elgin's "Tent City" were relocated to a hotel this week as work began...